25 C
New York
Saturday, July 26, 2025

Tag: oral inhibitors

Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases

Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOral inhibitors